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Mutations in PURA Cause Profound Neonatal
Hypotonia, Seizures, and Encephalopathy
in 5q31.3 Microdeletion Syndrome
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5q31.3 microdeletion syndrome is characterized by neonatal hypotonia, encephalopathy with or without epilepsy, and severe develop-
mental delay, and the minimal critical deletion interval harbors three genes. We describe 11 individuals with clinical features of 5q31.3
microdeletion syndrome and de novo mutations in PURA, encoding transcriptional activator protein Pur-a, within the critical region.
These data implicate causative PURA mutations responsible for the severe neurological phenotypes observed in this syndrome.To date, several individuals have been described as having
5q31.3 microdeletion syndrome.1–4 Shimojima et al.1 re-
ported two individuals with profound neonatal hypotonia,
feeding difficulties, an abnormal electroencephalogram
(EEG), hypomyelination, and severe psychomotor delay.1
Lennox-Gastaut syndrome was diagnosed in one of these
individuals, for whom seizures started at 12 months of
age. Additional affected individuals were subsequently re-
ported as presenting with marked hypotonia, respiratory
insufficiency with central or obstructive sleep apnea, swal-
lowing dysfunction, seizure-like episodes, epilepsy, and
neuroimaging abnormalities.2,3 Although the deletion
size varied from 2.6 to 5.0 Mb in the original report,1
subsequent individuals with smaller deletions narrowed
the critical region; the shortest overlapping segment
was approximately 101 kb and encompassed purine-rich
element binding protein A (PURA [MIM 600473; RefSeq
accession number NM_005859.4]), IgA-inducing protein
(IGIP), and cysteine-rich transmembrane module contain-
ing 1 (CYSTM1).3 Although PURA has earlier been pro-
posed as a candidate gene with mutations responsible for
the neurological phenotypes in this syndrome,3 no indi-
viduals with point mutations in this gene have been
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The AmericanWe identified 11 individuals with de novo heterozygous
mutations in the single-exon gene PURA among 2,908
consecutive subjects referred to the Whole Genome
Laboratory at Baylor College of Medicine from October
2011 to April 2014 for clinical exome sequencing.5
Approximately 70% of the individuals were pediatric sub-
jects with a variable spectrum of neurodevelopmental dis-
orders. Sequencing and data analysis were conducted as
previously described (Yang et al.5) and targeted ~20,000
genes, including the coding and UTR exons. Average
coverage for targeted regions was greater than 1303, and
more than 95% of the target bases were covered by at least
20 reads. To clarify the role of PURA in 5q31.3 microdele-
tion syndrome, we analyzed previously unreported PURA
variants found by clinical exome sequencing. Subjects
were enrolled in research studies approved by the institu-
tional review board of Baylor College of Medicine or the
University of Rochester, and informed consent was ob-
tained. Sanger sequencing confirmed the PURA mutations
in all individuals and validated the absence of the relevant
mutations in both parents for each of the 11 probands. For
each proband, samples were obtained from the biological
parents, and the transmission of multiple rare variants
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parental relationship. Of the identified PURA mutations,
four were truncating (three nonsense and one frameshift),
five were missense, and two were in-frame deletions
(Table 1; Figure 1A). None of these mutations were de-
tected in 1000 Genomes (release 20110521), dbSNP134,
the NHLBI Exome Sequencing Project Exome Variant
Server, or the database of Atherosclerosis Risk in Commu-
nities (exome data of ~6,000 subjects). No additional
contributing mutations in other genes were identified in
the 11 individuals with de novo PURA variants.
The phenotype of these 11 probands (Table 1; Table S1,
available online) is distinctly similar to that of 5q31 micro-
deletions encompassing this gene.1–3 All 11 individuals
presented at birth with significant hypotonia. Respiratory
insufficiency, including central and obstructive sleep
apnea and recurrent pulmonary aspiration, were fre-
quently observed. Early-onset feeding difficulties with
moderate dysphagia and evidence of tracheal aspiration
often necessitated nasogastric or gastric-tube feeding.
Myopathic facies with an open mouth and high arched
palate were common features (Figure 1B), as observed in
the subjects with 5q31.3 microdeletion syndrome.1–3 Hy-
pomyelination or myelin-maturation delay was noted on
brain-imaging studies in 4/11 individuals. Myoclonic jerks
in infancy were frequent, leading 6/11 children to progress
to develop epilepsy. An abnormal EEG was documented in
most individuals. Lennox-Gastaut syndrome was diag-
nosed in two individuals. Almost all of the affected chil-
dren were nonverbal and nonambulatory at the time of
evaluation. Prior to exome sequencing, many of these indi-
viduals had undergone extensive diagnostic evaluations,
including DNA sequencing and biochemical studies for ge-
netic conditions, such as Prader-Willi and Angelman syn-
dromes, spinal muscular atrophy, congenital disorders of
glycosylation, peroxisomal disorders, Rett syndrome, and
mitochondrial disease. Our results suggest that individuals
with PURA mutations share a recurring pattern of clinical
features composing a recognizable phenotype and poten-
tially establish a link between the severe neurodevelop-
mental profile of 5q31.3 microdeletion syndrome and
transcriptional activator protein Pur-a.6
PURA encodes a highly conserved 322 amino acid multi-
functional protein, Pur-a, that has important roles in DNA
replication, DNA transcription, and mRNA trafficking.7
Pur-a is required for postnatal development of the murine
brain and is involved in both neuronal proliferation and
maturation of dendrites.8,9 It has also been shown to be
important for the transport of specific mRNA molecules
to sites of translation in hippocampal neurons.10 Homozy-
gous Pura/mice appear normal at birth, but they develop
tremors and seizures at 2 weeks and die by 4 weeks of age.8
The number of neurons is severely lower in the cerebellum,
cortex, and hippocampus of these mice than in those of
age-matched Puraþ/þ controls.8 The development of den-
drites is also abnormal in the cerebellum and hippocampus
of Pura/mice.10 Pur-a has been found to colocalize with
fragile X mental retardation protein 1 homolog (FMRP) at580 The American Journal of Human Genetics 95, 579–583, Novembseveral sites throughout dendrites in mice.10 Pur-a, the
Drosophila ortholog of PURA, has been shown to interact
with the RNA transcript of FMR1 at the rCGG repeats
and has been implicated in neurodegeneration in the
model of fragile-X-associated tremor/ataxia syndrome.11
It is postulated that this interaction might be necessary
for FMR1 mRNA transport into dendrites. Similarly, Pur-a
has been shown to be involved in the transport of mRNAs
into the growing oocytes in Drosophila, given its expres-
sion in both follicle cells and germline cells.12 The crystal
structure of the protein reveals that the functionality of
Pur-a relies on the three conserved PUR motifs.13 The first
and second PUR motifs function in binding of single-
stranded DNA or RNA, whereas the third PUR motif is
involved in the dimerization of Pur-a. In previous studies,
targeted mutations in critical codons within the PUR
motifs abolished the ability of Pur-a to bind DNA or RNA
and impaired the translocation of Pur-a from follicle or
nurse cells into oocytes.12,13 The mutation in codon 97
of subject 4 overlaps theDrosophila critical codon 80 muta-
tion (causing p.Arg80Ala), previously12,13 shown to result
in reduced nucleic acid binding without affecting correct
folding. The missense and in-frame-deletion mutations
in our study are all located at conserved sites within
PUR motifs (Figure S1). Two in silico prediction tools,
PolyPhen-2 and SIFT, predict that the five missense muta-
tions have damaging effects (Table S2). Interestingly, given
that this is a single-exon gene and thus not likely subject
to nonsense-mediated decay, all truncating mutations
found in our series will result in loss or partial loss of
PUR motif(s).
To further elucidate the biological roles of PURA, we
employed the model organism Caenorhabditis elegans,
whose PURA ortholog is plp-1. The plp-1-null allele,
ok2155, has a 1,107 bp deletion encompassing part of
the promoter region and the first 255 bp of cDNA
sequence involving two exons (Figure S2). We found
that homozygous plp-1 (ok2155) mutants were sterile.
DAPI staining showed that oocytes were absent in the
plp-1 mutant (Figures 1C and 1D), suggesting a require-
ment of plp-1 for germline differentiation. The plp-1
mutants had defective locomotion, marked by a 3-fold
reduction in speed in comparison to wild-type animals
(Figure 1E; Movies S1 and S2). Compared to age-matched
wild-type worms, which showed normal movement, the
mutants exhibited minimal forward movement across
the culture medium. The observed defects might be
related to the impaired mRNA trafficking during oogen-
esis and neuronal activities. Together, these results suggest
the essential functions of plp-1 in both somatic and germ-
line tissues. Human PURA is expressed in the brain and
ovarian tissues (Figure S3) and might have roles similar
to those of plp-1.
In conclusion, we characterize the clinical features
and report de novo heterozygous PURA mutations in
multiple individuals with a significant neurodevelop-
mental phenotype recapitulating 5q31.3 microdeletioner 6, 2014
Table 1. Clinical Features of Individuals with PURA Mutations
Subject
Summary1 2 3 4 5 6 7 8 9 10 11
Gender male male male female female female female female male female female four males,
seven females
Age at
evaluation
6 months 7 months 10 months 21 months 23 months 2 years 2 years 5 years 12 years 12 years 15 years NA
Mutation c.812_814delTCT
(p.Phe271 del)
c.307_308delTC
(p.Ser103Hisfs*97)
c.556C>T
(p.Gln186*)
c.289A>G
(p.Lys97Glu)
c.299T>C
(p.Leu100Pro)
c.363C>G
(p.Tyr121*)
c.783C>G
(p.Tyr261*)
c.470T>A
(p.Met157Lys)
c.265G>C
(p.Ala89Pro)
c.263_265delTCG
(p.Ile88_
Ala89delinsThr)
c.596G>C
(p.Arg199Pro)
four
truncating,
seven
nontruncating
Inheritance de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo 11/11
Hypotonia þ þ þ þ þ þ þ þ þ þ þ 11/11
Feeding
difficulties
þ þ þ þ þ þ þ þ þ þ þ 11/11
Respiratory
difficulties
þ þ þ þ þ þ þ þ þ þ ND 10/10
Seizures þ  þ þ þ þ þ  þ þ þ 9/11
Seizure onset 3 weeks  neonatal ND 5 months 3 months neonatal  3 years 4 years ND NA
Seizure type myoclonic,
secondary
generalized tonic
 myoclonic
jerks
myoclonic
jerks,
exaggerated
startle
generalized
tonic clonic
myoclonic
jerks
myoclonic
jerks
 myoclonic,
generalized
tonic and
atonic
Lennox-Gastault
syndrome
Lennox-
Gastault
syndrome
NA
Abnormal
EEG
þ  þ ND ND þ þ ND þ þ þ NA
Psychomotor
delay
þ þ þ þ þ þ þ þ þ þ þ 11/11
Nonverbal ND ND ND þ þ þ þ þ þ þ þ 8/8
Ambulatory ND ND ND       walked at 3.5
years, ataxia
 1/8
Craniofacial
features
nondysmorphic high arched
palate, upturned
nose, simple
lobulation of ears,
intermittent
exotrophia
nondysmorphic myopathic
facies,
strabismus
myopathic
facies, tented
upper lip,
nystagmus
myopathic
facies
myopathic
facies,
left-eye
esotropia
nondysmorphic,
nystagmus,
strabismus
myopathic
facies, high
arched
palate,
nystagmus
myopathic facies,
high arched
palate, wide nasal
bridge and tip,
hypoplastic alae
nasi, strabismus,
myopia
nondysmorphic,
palpebral fissures
long, nystagmus
NA
See Table S1 for additional details of clinical presentations. Abbreviations are as follows: EEG, electroencephalogram; NA, not applicable; and ND, not determined because of availability or applicability.
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
5
,
5
7
9
–
5
8
3
,
N
o
ve
m
b
e
r
6
,
2
0
1
4
5
8
1
AB
C
D
E
Pur-
c.289A>G (p.Lys97Glu)
c.299T>C (p.Leu100Pro)
c.470T>A (p.Met157Lys)
c.596G>C (p.Arg199Pro)
c.812_814delTCT (p.Phe271del)
c.265G>C (p.Ala89Pro)
c.263_265delTCG (p.lle88_Ala89delinsThr)
c.307_308delTC (p.Ser103Hisfs*97)
c.363C>G (p.Tyr121*)
c.783C>G (p.Tyr261*)c.556C>T (p.Gln186*)
Figure 1. PURAMutations in the Affected
Human Subjects and Functions of the
PURAOrtholog in Model System C. elegans
(A) PURA is located in chromosomal region
5q31.2 (according to the UCSC Genome
Browser). A single exon (blue) encodes a
protein with three PUR motifs, as shown
in green. On the protein diagram,missense
and in-frame-deletion mutations are
brown, and the truncating mutations are
shown in red.
(B) Six subjects with de novo PURA muta-
tions are shown. The craniofacial features
are mainly characterized by myopathic
facies. For whom clinical photographs are
shown, informed consent specifically
agreeing to publish these photographs in
medical publications was obtained.
(C) DNA staining in the germline of a wild-
type C. elegans animal. Yellow dashed lines
indicate differentiated oocytes.
(D) Oocytes were absent in the plp-1-
mutant animal with smaller gonads.
Wild-type (N2) and RB1711 (plp-
1(ok2155)IV) animals were obtained from
the Caenorhabditis Genetics Center.
C. elegans were grown on standard nema-
tode growth media plates (containing
5 mg/l cholesterol) with E. coli OP50 at
25C according to standard protocols.
DAPI staining was performed at room tem-
perature. The germline was dissected out
from young adult worms.
(E) Average speed of individual worm
movement (wild-type n ¼ 14, plp-1 n ¼
12). The p value was obtained by a one-
tailed Student’s t test. Error bars in the
scattered dot plot represent the mean and
the SEM. Spontaneous movement of age-
synchronized worms on standard worm
plates was recorded for 15 s with an
SMZ1500 stereo microscope (Nikon) connected to a C11440 camera (Hamamatsu). Individual worms were tracked with NIS Elements
AR 2D tracking imaging software (Nikon), and the average velocity (mm/s) was calculated. Representative recording of wild-type worms
and plp-1 mutants are shown in Movies S1 and S2, respectively.syndrome. Considering all 2,117 pediatric subjects who
had a neurodevelopmental disorder and were studied
by clinical exome sequencing in our laboratory, the 11
heterozygous mutations in PURA account for ~0.52% and
are exceeded only by those in well-established genes AT-
rich interactive domain 1B (SWI1-like) (ARID1B [MIM
614556]; 21 subjects [0.99%]) and ankyrin repeat domain
11 (ANKRD11 [MIM 611192]; 13 subjects [0.61%]).
Notably, our observed frequency of pathogenic events in
ARID1B is consistent with the 0.9% rate previously re-
ported by Hoyer et al.14 PURA mutations should be
considered in the evaluation of infants with profound
neonatal hypotonia, myoclonic jerks, respiratory insuffi-
ciency, and an abnormal EEG. Although further investiga-
tions are essential for understanding the effects of PURA
haploinsufficiency on encephalopathy with or without
epilepsy, this study is an important step toward the
clinical and molecular characterization of this disease,
which is typically associated with a significant neurolog-
ical outcome.582 The American Journal of Human Genetics 95, 579–583, NovembSupplemental Data
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